Roles of Ki67 in Breast Cancer - Important for Management? |
Yip, CH
(Department of Surgery, Subang Jaya Medical Centre)
Bhoo-Pathy, N (Department of Social and Preventive Medicine, University of Malaya) Daniel, JM (Department of Pathology, Subang Jaya Medical Centre) Foo, YC (Department of Clinical Oncology, Subang Jaya Medical Centre) Mohamed, AK (Department of Clinical Oncology, Subang Jaya Medical Centre) Abdullah, MM (Department of Clinical Oncology, Subang Jaya Medical Centre) Ng, YS (Department of Clinical Oncology, Subang Jaya Medical Centre) Yap, BK (Department of Clinical Oncology, Subang Jaya Medical Centre) Pathmanathan, R (Department of Pathology, Subang Jaya Medical Centre) |
1 | Malaysian Clinical Practice Guidelines for the Management of Breast Cancer Nov 2010 http://www.moh.gov.my. |
2 | Andre F, Arnedos M, Goubar A, et al (2015). Ki67-no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol. |
3 | Cheang MC, Chia SK, Voduc D, et al (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst, 101, 736-50. DOI |
4 | Cuzick J, Dowsett M, Pineda S, et al (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol, 29, 4273-8. DOI |
5 | de Azambuja E, Cardoso F, de Castro G, Jr., et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13. DOI |
6 | Dowsett M, Nielsen TO, A'Hern R, et al (2011). Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst, 103, 1656-64. DOI |
7 | Dowsett M, Smith IE, Ebbs SR, et al (2007). Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst, 99, 167-70. DOI |
8 | Goldhirsch A, Winer EP, Coates AS, et al (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 24, 2206-23. DOI |
9 | Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the st. gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol, 22, 1736-47. DOI |
10 | Hammond ME, Hayes DF, Dowsett M, et al (2010). American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 28, 2784-95. DOI |
11 | Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139, 539-52. DOI |
12 | Jonat W, Arnold N (2011). Is the Ki-67 labelling index ready for clinical use? Ann Oncol, 22, 500-2. DOI |
13 | Trihia H, Murray S, Price K, et al (2003). Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer, 97, 1321-31. DOI |
14 | Keam B, Im SA, Lee KH, et al (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 13, 22. |
15 | Nishimura R, Osako T, Okumura Y, et al (2010). Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer, 17, 269-75. DOI |
16 | Spyratos F, Ferrero-Pous M, Trassard M, et al (2002). Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer, 94, 2151-9. DOI |
17 | Urruticoechea A, Smith IE, Dowsett M (2005). Proliferation marker Ki-67 in early breast cancer. J Clin Oncol, 23, 7212-20. DOI |
18 | Wiesner FG, Magener A, Fasching PA, et al (2009). Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast, 18, 135-41. DOI |
19 | Wishart GC, Azzato EM, Greenberg DC, et al (2010). PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res, 12, R1. DOI |
20 | Wolff AC, Hammond ME, Hicks DG, et al (2014). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. Arch Pathol Lab Med, 138, 241-56. DOI |